Olanzapine versus haloperidol in the treatment of acute mania: Clinical outcomes, health-related quality of life and work status

Lizheng Shi, M. A. Namjoshi, F. Zhang, G. Gandhi, E. T. Edgell, M. Tohen, Alan Breier, J. M. Haro

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder. This double-blind, randomized controlled trial, comparing flexible dosing of olanzapine (5-20 mg/day, n = 234) to haloperidol (3-15 mg/day, n = 219), consisted of a 6-week acute phase, followed by a 6-week continuation phase. Symptomatic remission rates were similar for olanzapine- and haloperidol-treated patients at weeks 6 and 12. At week 6, significant changes in five dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [general health (P=0.010), physical functioning (P

Original languageEnglish (US)
Pages (from-to)227-237
Number of pages11
JournalInternational Clinical Psychopharmacology
Volume17
Issue number5
StatePublished - Sep 2002

Fingerprint

olanzapine
Haloperidol
Bipolar Disorder
Quality of Life
Health Surveys
Therapeutics
Randomized Controlled Trials
Outcome Assessment (Health Care)
Health

Keywords

  • Bipolar disorder
  • Functional outcomes
  • Olanzapine
  • Quality of life

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Shi, L., Namjoshi, M. A., Zhang, F., Gandhi, G., Edgell, E. T., Tohen, M., ... Haro, J. M. (2002). Olanzapine versus haloperidol in the treatment of acute mania: Clinical outcomes, health-related quality of life and work status. International Clinical Psychopharmacology, 17(5), 227-237.

Olanzapine versus haloperidol in the treatment of acute mania : Clinical outcomes, health-related quality of life and work status. / Shi, Lizheng; Namjoshi, M. A.; Zhang, F.; Gandhi, G.; Edgell, E. T.; Tohen, M.; Breier, Alan; Haro, J. M.

In: International Clinical Psychopharmacology, Vol. 17, No. 5, 09.2002, p. 227-237.

Research output: Contribution to journalArticle

Shi, Lizheng ; Namjoshi, M. A. ; Zhang, F. ; Gandhi, G. ; Edgell, E. T. ; Tohen, M. ; Breier, Alan ; Haro, J. M. / Olanzapine versus haloperidol in the treatment of acute mania : Clinical outcomes, health-related quality of life and work status. In: International Clinical Psychopharmacology. 2002 ; Vol. 17, No. 5. pp. 227-237.
@article{b362106f99d04436a54a15fb710bbfda,
title = "Olanzapine versus haloperidol in the treatment of acute mania: Clinical outcomes, health-related quality of life and work status",
abstract = "We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder. This double-blind, randomized controlled trial, comparing flexible dosing of olanzapine (5-20 mg/day, n = 234) to haloperidol (3-15 mg/day, n = 219), consisted of a 6-week acute phase, followed by a 6-week continuation phase. Symptomatic remission rates were similar for olanzapine- and haloperidol-treated patients at weeks 6 and 12. At week 6, significant changes in five dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [general health (P=0.010), physical functioning (P",
keywords = "Bipolar disorder, Functional outcomes, Olanzapine, Quality of life",
author = "Lizheng Shi and Namjoshi, {M. A.} and F. Zhang and G. Gandhi and Edgell, {E. T.} and M. Tohen and Alan Breier and Haro, {J. M.}",
year = "2002",
month = "9",
language = "English (US)",
volume = "17",
pages = "227--237",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Olanzapine versus haloperidol in the treatment of acute mania

T2 - Clinical outcomes, health-related quality of life and work status

AU - Shi, Lizheng

AU - Namjoshi, M. A.

AU - Zhang, F.

AU - Gandhi, G.

AU - Edgell, E. T.

AU - Tohen, M.

AU - Breier, Alan

AU - Haro, J. M.

PY - 2002/9

Y1 - 2002/9

N2 - We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder. This double-blind, randomized controlled trial, comparing flexible dosing of olanzapine (5-20 mg/day, n = 234) to haloperidol (3-15 mg/day, n = 219), consisted of a 6-week acute phase, followed by a 6-week continuation phase. Symptomatic remission rates were similar for olanzapine- and haloperidol-treated patients at weeks 6 and 12. At week 6, significant changes in five dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [general health (P=0.010), physical functioning (P

AB - We aimed to compare clinical outcomes, health-related quality of life (HRQOL) and work status associated with olanzapine and haloperidol treatment in patients with bipolar disorder. This double-blind, randomized controlled trial, comparing flexible dosing of olanzapine (5-20 mg/day, n = 234) to haloperidol (3-15 mg/day, n = 219), consisted of a 6-week acute phase, followed by a 6-week continuation phase. Symptomatic remission rates were similar for olanzapine- and haloperidol-treated patients at weeks 6 and 12. At week 6, significant changes in five dimensions of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [general health (P=0.010), physical functioning (P

KW - Bipolar disorder

KW - Functional outcomes

KW - Olanzapine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=0036738217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036738217&partnerID=8YFLogxK

M3 - Article

C2 - 12177585

AN - SCOPUS:0036738217

VL - 17

SP - 227

EP - 237

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -